Agenus Inc. Positive Cervical Cancer Provides Impetus to its Robust Cancer Pipeline
Agenus Inc (NASDAQ: AGEN), a clinical-stage immune-oncology company developing innovative therapies for treatment of cancer, announced the grant of a Fast Track designation for investigation of balstilimab [PD-1] in combination with zalifrelimab [CTLA-4] for the treatment of patients with relapsed or refractory metastatic cervical cancer. [caption...
